| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $190.9M | — | +14.5% |
| Cost of Revenue | $4.3M | — | -20.7% |
| R&D Expense | $8.5M | — | +14.2% |
| SG&A Expense | $9.2M | — | +9.1% |
| Operating Income | $23.4M | — | +192.8% |
| Pre-tax Income | $24.4M | — | +180.9% |
| Income Tax | $5.7M | — | +732.0% |
| Net Income | $18.7M | — | +133.7% |
| EPS (Basic) | $0.52 | — | +136.4% |
| EPS (Diluted) | $0.51 | — | +142.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $178.5M | +4.2% | +42.8% |
| Accounts Receivable | $71.8M | -4.5% | +16.1% |
| Current Assets | $257.1M | +0.3% | +32.3% |
| Total Assets | $324.0M | -0.9% | +39.6% |
| Current Liabilities | $81.9M | -6.1% | +1.8% |
| Total Liabilities | $83.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $29.6M | — | +27.0% |
| Investing Cash Flow | -$1.5M | — | -35.5% |
| Financing Cash Flow | -$20.9M | — | -3229.3% |
| +0.6% |
| Stockholders' Equity | $240.9M | +1.2% | +61.1% |